ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 393

Physical Activity Monitoring Using Wrist-Worn Accelerometer in the Assessment and Follow-up of Patients with Myositis

Océane Landon-Cardinal1, Damien Bachasson2, Perrine Guillaume1, Mathieu Vautier1, Nicolas Champtiaux1, Baptiste Hervier1, Aude Rigolet1, Olivier Benveniste1, Jean-Yves Hogrel2 and Yves Allenbach1, 1Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, 2Institute of Myology, Pitié-Salpêtrière University Hospital, Paris, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Assessment, myopathy, Myositis, outcome measures and physical activity

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Wrist-worn accelerometers allow the objective estimation of physical activity (PA) in daily life. Recently, the ENMC workshop on outcome measures in myositis suggested to implement PA monitoring for improving patient follow-up. This study aimed to evaluate PA monitoring in the assessment of myositis patients in daily clinical practice.

Methods: Included patients had a diagnosis of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) or overlap myositis (OM). They either had a new-onset or relapsing myositis, a stable disease on maintenance therapy or were undergoing immunosuppressant tapering. Patients were evaluated at baseline and 6 months (M6). IMACS core-set measures, ACR/EULAR improvement score, muscle endurance testing, deltoid and psoas strength using hand-held dynamometry, 14-days raw acceleration data (expressed both as mean daily Euclidean norm minus 1 g (ENMO) and as standard deviations from healthy control Z-score), and quality of life (QoL) questionnaires were recorded. Relationships between variables were investigated using Spearman correlation coefficient (ρ) and random forest (RF) regressions.

Results: Fifty-five patients (16 OM, 27 IMNM and 12 DM) were included. At baseline, 67% had ENM0 Z-score lower than 1 (mean Z-scores −1.09±0.94). At M0, ENMO mainly correlated with manual muscle testing 8 (MMT8, ρ=0.44, p<0.001), creatinine level (ρ=0.43, p<0.001), HAQ (ρ=−0.53, p<0.0001), and SF-36-physical functioning (ρ=0.40, p<0.01). According to RF regressions, most important features associated with ENMO Z-scores were HAQ, SF-36-physical functioning/energy/pain and disease duration.

At M6, ENMO changes mainly correlated to changes in muscle enzymes (ρ=−0.44, p<0.01), MMT8 (ρ=0.44, p<0.01), and depression score (ρ=−0.44, p=0.013). According to the RF regression, most important features associated with ENMO changes were absolute change in MMT8, HAQ, SF-36-physical functioning, physician global assessment, and depression score.

ENMO changes were correlated with ACR/EULAR improvement score (ρ=0.48, p<0.01) and all patients, except one, achieving a major improvement had an absolute change of ENMO >5 mg/day. Yet, only 50% with moderate improvement (ACR/EULAR) had an improvement in ENMO and variable changes in ENMO were observed in patients with unchanged and minimally improved status.

Conclusion: PA levels were smaller in myositis patients at baseline compared to healthy controls and were correlated with MMT8 and QoL. Patients with major ACR/EULAR improvements at follow-up were associated with consistent changes in PA, while other displayed heterogeneous changes in PA.


Disclosure: O. Landon-Cardinal, None; D. Bachasson, None; P. Guillaume, None; M. Vautier, None; N. Champtiaux, None; B. Hervier, None; A. Rigolet, None; O. Benveniste, None; J. Y. Hogrel, None; Y. Allenbach, None.

To cite this abstract in AMA style:

Landon-Cardinal O, Bachasson D, Guillaume P, Vautier M, Champtiaux N, Hervier B, Rigolet A, Benveniste O, Hogrel JY, Allenbach Y. Physical Activity Monitoring Using Wrist-Worn Accelerometer in the Assessment and Follow-up of Patients with Myositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/physical-activity-monitoring-using-wrist-worn-accelerometer-in-the-assessment-and-follow-up-of-patients-with-myositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physical-activity-monitoring-using-wrist-worn-accelerometer-in-the-assessment-and-follow-up-of-patients-with-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology